Sept. 4, 2025—MeMed announced that several oral presentations at the American College of Emergency Physicians Scientific Assembly 2025, Sept. 7–10 in Salt Lake City, will showcase clinical evidence supporting the utility of MeMed BV, an FDA-cleared test that distinguishes between bacterial and viral infections based on the body’s immune response. The presentations span multiple leading U.S. medical centers and include real-world data, randomized controlled trial results, and insights into the test’s role in supporting clinical decisions with challenging patient populations, such as people who are immunocompromised and the elderly. “Collectively, these studies underscore MeMed BV’s potential to support decision-making in emergency departments and aid clinicians in their efforts to reduce unnecessary antibiotic use and unnecessary admissions while lowering health care costs,” according to a press release from the company.
Webinars and Sponsored Roundtables — Register Now
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, July 21, 2026, 11:00-11:30 AM CT
- Explain how transparency and manufacturer partnerships improve quality, consistency, and decision-making confidence in specimen management.
- Evaluate blood collection tubes beyond cost and commodity assumptions, incorporating clinical impact and risk into decision-making.
- Assess the potential risk points when using a blood collection device that has not been cleared for a specific purpose.
Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY